Table 1.
On-going clinical trials for combination of immune checkpoint inhibitor and radiation
| NCT number | Institution | Phase | Disease | Intervention | Estimated enrollment | Primary endpoint |
| NCT03482102 | United States (MGH) | II | Locally advanced/ unresectable or metastatic disease HCC or biliary tract cancer | Experimental: Tremelimumab + Durvalumab + EBRT | 70 | Best overall response rate |
| NCT03203304 | United States (UCh) | I | HCC | SBRT Nivolumab → +/- ipilimumab + SBRT (8 Gy × 5) | 50 | Number of participants with adverse events |
| NCT03316872 | Canada (UHN) | II | HCC showing progression after sorafenib | Pembrolizumab + SBRT | 30 | Overall response rate |
| NCT03812562 | United States (NU) | I | HCC intended to be resected | 90Y SIRT → Nivolumab | 12 | Recurrence rate |
| NCT03033446 | Singapore (NCC) | II | HCC not suitable for resection or transplant | 90Y SIRT → Nivolumab | 40 | Response rate |
| NCT02837029 | United States (NU) | I/Ib | HCC stage IIIA - IVB | 90Y SIRT → Nivolumab | 35 | Maximum tolerated dose |
| NCT03099564 | United States (UNC) | I | HCC | 90Y SIRT + Pembrolizumab | 30 | Progression-free survival |
MGH: Massachusetts General Hospital; HCC: Hepatocellular carcinoma; EBRT: External beam radiotherapy; UCh: University of Chicago; SBRT: Stereotactic body radiotherapy; UHN: University Health Network; NU: Northwestern University; SIRT: Selective internal radiation therapy; NCC: National Cancer Center; UNC: University of North Carolina.